In our study, we found that the non-selective β2-AR antagonist propranolol inhibits NB growth and that β2, but not β1, antagonists were active against a panel of human NB cell lines at doses comparable to those previously reported in vitro for other cancer cell types. This evidence concerns the gene ADRB2 and cancer.